ArticlePloS one2012
Modulation of intestinal inflammation by yeasts and cell wall extracts: strain dependence and unexpected anti-inflammatory role of glucan fractions.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Trial
- Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome.International journal of colorectal disease · 2020Trial
- Remission in Crohn's disease is accompanied by alterations in the gut microbiota and mucins production.Scientific reports · 2019Trial
- Trial
- Fungal chitin dampens inflammation through IL-10 induction mediated by NOD2 and TLR9 activation.PLoS pathogens · 2014Trial
- Yeast as a Model for Human Disease.International journal of molecular sciences · 2026Review
- Performance, blood parameters, ruminal fermentation and microbial community of dairy cows supplemented with Saccharomyces cerevisiae fermentation product from dry-off to early lactation.Journal of animal science · 2026Article
- Yeasts in the gastrointestinal tract.FEMS yeast research · 2026Review
- The role of the mycobiome in host physiology and disease: insights from rodent models.Lab animal · 2025Review
- How Do Polyphenol-Rich Foods Prevent Oxidative Stress and Maintain Gut Health?Microorganisms · 2024Review
- A Probiotic Amylase Blend Positively Impacts Gut Microbiota Modulation in a Randomized, Placebo-Controlled, Double-Blind Study.Life (Basel, Switzerland) · 2024Article
- Heat-KilledNutrients · 2024Article
- Characteristics ofMicrobiology spectrum · 2024Article
- Healthy Diet and Lifestyle Improve the Gut Microbiota and Help Combat Fungal Infection.Microorganisms · 2023Review
- Changes in the gut mycobiome in pediatric patients in relation to the clinical activity of Crohn's disease.World journal of gastroenterology · 2023Article
- Editorial of Special Issue "Human Pathogenic Fungi: Host-Pathogen Interactions and Virulence".Microorganisms · 2023Article
- Enhanced probiotic potential ofFrontiers in microbiology · 2023Article
- Hepatoprotective Properties of Water Kefir: A Traditional Fermented Drink and Its Potential Role.International journal of preventive medicine · 2023Review
- Oleic Acid and Palmitic Acid fromMicroorganisms · 2022Article
- Human Gut Mycobiome and Fungal Community Interaction: The Unknown Musketeer in the Chemotherapy Response Status in Bladder Cancer.European urology open science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yeasts and their glycan components can have a beneficial or adverse effect on intestinal inflammation. Previous research has shown that the presence of Saccharomyces cerevisiae var. boulardii (Sb) reduces intestinal inflammation and colonization by Candida albicans. The aim of this study was to identify dietary yeasts, which have comparable effects to the anti-C. albicans and anti-inflammatory properties of Sb and to assess the capabilities of yeast cell wall components to modulate intestinal inflammation. Mice received a single oral challenge of C. albicans and were then given 1.5% dextran-sulphate-sodium (DSS) for 2 weeks followed by a 3-day restitution period. S. cerevisiae strains (Sb, Sc1 to Sc4), as well as mannoprotein (MP) and β-glucan crude fractions prepared from Sc2 and highly purified β-glucans prepared from C. albicans were used in this curative model, starting 3 days after C. albicans challenge. Mice were assessed for the clinical, histological and inflammatory responses related to DSS administration. Strain Sc1-1 gave the same level of protection against C. albicans as Sb when assessed by mortality, clinical scores, colonization levels, reduction of TNFα and increase in IL-10 transcription. When Sc1-1 was compared with the other S. cerevisiae strains, the preparation process had a strong influence on biological activity. Interestingly, some S. cerevisiae strains dramatically increased mortality and clinical scores. Strain Sc4 and MP fraction favoured C. albicans colonization and inflammation, whereas β-glucan fraction was protective against both. Surprisingly, purified β-glucans from C. albicans had the same protective effect. Thus, some yeasts appear to be strong modulators of intestinal inflammation. These effects are dependent on the strain, species, preparation process and cell wall fraction. It was striking that β-glucan fractions or pure β-glucans from C. albicans displayed the most potent anti-inflammatory effect in the DSS model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.